ACM
VRTX icon

ADAR1 Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

ADAR1 Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,075
Closed -$6.73M – 346
2026
Q1 		$6.73M Buy
15,075
+1,359
+10% +$634K 0.4% 62
2025
Q4 		$6.22M Buy
13,716
+6,716
+96% +$2.89M 0.46% 46
2025
Q3 		$2.74M Buy
+7,000
New +$2.93M 0.26% 68

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ADAR1 Capital Management's VRTX Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 15,075 shares — an estimated $6.73M sold.

ADAR1 Capital Management first reported a position in VRTX in Q3 2025 and held it in 3 quarters. The position peaked at $6.73M in Q1 2026. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • ADAR1 Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 15,075 Vertex Pharmaceuticals shares in Q2 2026, an estimated $6.73M.
  • ADAR1 Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • ADAR1 Capital Management's Vertex Pharmaceuticals position peaked at $6.73M in Q1 2026.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.